Literature DB >> 26615422

13-Oxyingenol dodecanoate, a cytotoxic ingenol derivative, induces mitochondrial apoptosis and caspase-dependent Akt decrease in K562 cells.

Ming Liu1, Weiyi Zhang1, Genzhu Wang1, Xiaoping Song1, Xingzeng Zhao2, Xiangyun Wang3, Xin Qi1, Jing Li4.   

Abstract

13-Oxyingenol dodecanoate (13OD) is an ingenol derivative prepared from Chinese traditional medicine Euphorbia kansui without any report about its bioactivity. The present study demonstrated for the first time that 13OD displayed potent cytotoxicity against chronic myeloid leukemia K562 cells in vitro. 13OD inhibited proliferation, induced G2/M phase arrest, and exhibited potent apoptotic activity in K562 cells. In K562 cells, 13OD disrupted the mitochondrial membrane potential and induced high level of ROS, which played an indispensable role in 13OD-induced apoptosis. Further investigations on the molecular mechanisms revealed that total Akt protein level was decreased in a caspase-dependent way after treatment with 13OD; in addition, ERK was activated by 13OD, and this activation played a protective role in 13OD stimulation. Altogether, these results revealed that the cytotoxic ingenol derivative 13OD induced apoptosis with novel mechanisms for the proapoptotic function in cancer cells, and suggested that 13OD may serve as a lead template for rational drug design and for future anticancer agent development.

Entities:  

Keywords:  13-Oxyingenol dodecanoate; Akt; Apoptosis; Euphorbia kansui; mTOR

Mesh:

Substances:

Year:  2015        PMID: 26615422     DOI: 10.1007/s13277-015-4495-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors.

Authors:  Gregory J Gores; Scott H Kaufmann
Journal:  Genes Dev       Date:  2012-02-15       Impact factor: 11.361

2.  Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer.

Authors:  Xifu Liang; Gunnar Grue-Sørensen; Kristoffer Månsson; Per Vedsø; Anke Soor; Martin Stahlhut; Malene Bertelsen; Karen Margrethe Engell; Thomas Högberg
Journal:  Bioorg Med Chem Lett       Date:  2013-08-14       Impact factor: 2.823

3.  Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells.

Authors:  Maria Serova; Aïda Ghoul; Karim A Benhadji; Sandrine Faivre; Christophe Le Tourneau; Esteban Cvitkovic; Francois Lokiec; Janet Lord; Steven M Ogbourne; Fabien Calvo; Eric Raymond
Journal:  Mol Cancer Ther       Date:  2008-04       Impact factor: 6.261

Review 4.  Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.

Authors:  Siu-Fun Wong; Hamid Mirshahidi
Journal:  Ann Pharmacother       Date:  2011-06-13       Impact factor: 3.154

5.  Tumor necrosis factor-{alpha} decreases Akt protein levels in 3T3-L1 adipocytes via the caspase-dependent ubiquitination of Akt.

Authors:  Edward A Medina; Robert R Afsari; Tommer Ravid; S Sianna Castillo; Kent L Erickson; Tzipora Goldkorn
Journal:  Endocrinology       Date:  2005-03-03       Impact factor: 4.736

6.  Characterization of the interaction of ingenol 3-angelate with protein kinase C.

Authors:  Noemi Kedei; Daniel J Lundberg; Attila Toth; Peter Welburn; Susan H Garfield; Peter M Blumberg
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

Review 7.  Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.

Authors:  TaeHun Kim; Gyochang Keum; Ae Nim Pae
Journal:  Expert Opin Ther Pat       Date:  2013-05-04       Impact factor: 6.674

8.  Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90.

Authors:  Xiaoping Song; Zhimin Zhao; Xin Qi; Shuai Tang; Qiang Wang; Tianjiao Zhu; Qianqun Gu; Ming Liu; Jing Li
Journal:  Oncotarget       Date:  2015-03-10

9.  Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

Authors:  K A Benhadji; M Serova; A Ghoul; E Cvitkovic; C Le Tourneau; S M Ogbourne; F Lokiec; F Calvo; P Hammel; S Faivre; E Raymond
Journal:  Br J Cancer       Date:  2008-12-02       Impact factor: 7.640

10.  Ingenol mebutate: A novel topical drug for actinic keratosis.

Authors:  Suruchi Aditya; Sanjeev Gupta
Journal:  Indian Dermatol Online J       Date:  2013-07
View more
  1 in total

1.  Marine Streptomyces sp. derived antimycin analogues suppress HeLa cells via depletion HPV E6/E7 mediated by ROS-dependent ubiquitin-proteasome system.

Authors:  Weiyi Zhang; Qian Che; Hongsheng Tan; Xin Qi; Jing Li; Dehai Li; Qianqun Gu; Tianjiao Zhu; Ming Liu
Journal:  Sci Rep       Date:  2017-02-08       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.